Buparlisib (BioDeep_00000858961)
代谢物信息卡片
Buparlisib
化学式: C18H21F3N6O2 (410.1678002)
中文名称: 5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4
InChI: InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)
描述信息
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:71954
- KEGGdrug: D10584
- PubChem: 16654980
- DrugBank: DB11666
- ChEMBL: CHEMBL2017974
- CAS: 1202777-78-3
- CAS: 944396-07-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Anja Welt, Marcel Wiesweg, Sarah Theurer, Wolfgang Abenhardt, Matthias Groschek, Lothar Müller, Jan Schröder, Mitra Tewes, Marco Chiabudini, Karin Potthoff, Agnes Bankfalvi, Norbert Marschner, Martin Schuler, Frank Breitenbücher. Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
Cancer medicine.
2020 07; 9(13):4527-4539. doi:
10.1002/cam4.3092. [PMID: 32352244] - Jingyun Wang, Meng Ming, Lin Yu, Guangliang Chen, Nan Hao, Yuqi Meng, Lina Fang. LC-MS/MS determination of buparlisib, a phosphoinositide 3 kinase inhibitor in rat plasma: Application to a pharmacokinetic study.
Biomedical chromatography : BMC.
2020 Jun; 34(6):e4816. doi:
10.1002/bmc.4816. [PMID: 32110828] - Taofeek K Owonikoko, R Donald Harvey, Bradley Carthon, Zhengjia Chen, Colleen Lewis, Hanna Collins, Chao Zhang, David H Lawson, Olatunji B Alese, Mehmet Asim Bilen, Gabriel L Sica, Conor E Steuer, Walid L Shaib, Christina Wu, Wayne B Harris, Mehmet Akce, Ragini R Kudchagkar, Bassel F El-Rayes, Sagar Lonial, Suresh S Ramalingam, Fadlo Raja Khuri. A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 06; 26(11):2497-2505. doi:
10.1158/1078-0432.ccr-19-2697. [PMID: 32005746] - Paul Tuijnenburg, Daan J Aan de Kerk, Machiel H Jansen, Ben Morris, Cor Lieftink, Roderick L Beijersbergen, Ester M M van Leeuwen, Taco W Kuijpers. High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells.
European journal of immunology.
2020 01; 50(1):73-85. doi:
10.1002/eji.201948241. [PMID: 31621069] - Shengfei Wang, Xiaomin Niu, Xiao Bao, Qin Wang, Jianping Zhang, Shun Lu, Yongjun Wang, Ling Xu, Mingwei Wang, Jie Zhang. The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
Oncology reports.
2019 May; 41(5):2636-2646. doi:
10.3892/or.2019.7080. [PMID: 30896825] - Patrick Y Wen, Mehdi Touat, Brian M Alexander, Ingo K Mellinghoff, Shakti Ramkissoon, Christine S McCluskey, Kristine Pelton, Sam Haidar, Sankha S Basu, Sarah C Gaffey, Loreal E Brown, Juan Emmanuel Martinez-Ledesma, Shaofang Wu, Jungwoo Kim, Wei Wei, Mi-Ae Park, Jason T Huse, John G Kuhn, Mikael L Rinne, Howard Colman, Nathalie Y R Agar, Antonio M Omuro, Lisa M DeAngelis, Mark R Gilbert, John F de Groot, Timothy F Cloughesy, Andrew S Chi, Thomas M Roberts, Jean J Zhao, Eudocia Q Lee, Lakshmi Nayak, James R Heath, Laura L Horky, Tracy T Batchelor, Rameen Beroukhim, Susan M Chang, Azra H Ligon, Ian F Dunn, Dimpy Koul, Geoffrey S Young, Michael D Prados, David A Reardon, W K Alfred Yung, Keith L Ligon. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2019 03; 37(9):741-750. doi:
10.1200/jco.18.01207. [PMID: 30715997] - Haoxun Wang, Jinghui Zhang, Guofeng You. The mechanistic links between insulin and human organic anion transporter 4.
International journal of pharmaceutics.
2019 Jan; 555(?):165-174. doi:
10.1016/j.ijpharm.2018.11.040. [PMID: 30453017] - Denise Rageot, Thomas Bohnacker, Anna Melone, Jean-Baptiste Langlois, Chiara Borsari, Petra Hillmann, Alexander M Sele, Florent Beaufils, Marketa Zvelebil, Paul Hebeisen, Wolfgang Löscher, John Burke, Doriano Fabbro, Matthias P Wymann. Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
Journal of medicinal chemistry.
2018 11; 61(22):10084-10105. doi:
10.1021/acs.jmedchem.8b01262. [PMID: 30359003] - Autumn J McRee, Paul K Marcom, Dominic T Moore, William C Zamboni, Zachary A Kornblum, Zhiyuan Hu, Rachel Phipps, Carey K Anders, Katherine Reeder-Hayes, Lisa A Carey, Karen E Weck, Charles M Perou, E Claire Dees. A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
Clinical breast cancer.
2018 08; 18(4):289-297. doi:
10.1016/j.clbc.2017.10.014. [PMID: 29153866] - Mark C de Gooijer, Ping Zhang, Levi C M Buil, Ceren H Çitirikkaya, Nishita Thota, Jos H Beijnen, Olaf van Tellingen. Buparlisib is a brain penetrable pan-PI3K inhibitor.
Scientific reports.
2018 Jul; 8(1):10784. doi:
10.1038/s41598-018-29062-w. [PMID: 30018387] - Christophe Massard, Kim Nguyen Chi, Daniel Castellano, Johann de Bono, Gwenaelle Gravis, Luc Dirix, Jean-Pascal Machiels, Alain Mita, Begoña Mellado, Sabine Turri, Joan Maier, Denes Csonka, Arunava Chakravartty, Karim Fizazi. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
European journal of cancer (Oxford, England : 1990).
2017 05; 76(?):36-44. doi:
10.1016/j.ejca.2017.01.024. [PMID: 28282611] - Nicole Willemsen-Seegers, Joost C M Uitdehaag, Martine B W Prinsen, Judith R F de Vetter, Jos de Man, Masaaki Sawa, Yusuke Kawase, Rogier C Buijsman, Guido J R Zaman. Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.
Journal of molecular biology.
2017 02; 429(4):574-586. doi:
10.1016/j.jmb.2016.12.019. [PMID: 28043854] - Rana R McKay, Guillermo De Velasco, Lillian Werner, Joaquim Bellmunt, Lauren Harshman, Christopher Sweeney, Jonathan E Rosenberg, Michelle Hirsch, Sabina Signoretti, Eliezer M Van Allen, Meghara Walsh, Ulka Vaishampayan, David F McDermott, Toni K Choueiri. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
Cancer.
2016 Aug; 122(15):2389-98. doi:
10.1002/cncr.30056. [PMID: 27198170] - Cynthia X Ma, Jingqin Luo, Michael Naughton, Foluso Ademuyiwa, Rama Suresh, Malachi Griffith, Obi L Griffith, Zachary L Skidmore, Nicholas C Spies, Avinash Ramu, Lee Trani, Timothy Pluard, Gayathri Nagaraj, Shana Thomas, Zhanfang Guo, Jeremy Hoog, Jing Han, Elaine Mardis, Craig Lockhart, Matthew J Ellis. A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016 Apr; 22(7):1583-91. doi:
10.1158/1078-0432.ccr-15-1745. [PMID: 26563128] - Cheng Huang, Guang Li, Haojian Dong, Shuo Sun, Haimin Chen, Demou Luo, Ling Sun, Xida Li, Zhujun Chen, Huijian Yang, Shuisheng Wei, Yingling Zhou. Arg⁹⁷² insulin receptor substrate-1 inhibits endothelial nitric oxide synthase expression in human endothelial cells by upregulating microRNA-155.
International journal of molecular medicine.
2015 Jul; 36(1):239-48. doi:
10.3892/ijmm.2015.2192. [PMID: 25902041] - Sally K Martin, Zhen Ying Gan, Stephen Fitter, Luen B To, Andrew C W Zannettino. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Leukemia research.
2015 Mar; 39(3):380-7. doi:
10.1016/j.leukres.2014.12.015. [PMID: 25624048] - Christian Lanshoeft, Olivier Heudi, Luc Alexis Leuthold, Götz Schlotterbeck, Walid Elbast, Franck Picard, Olivier Kretz. Laser diode thermal desorption atmospheric pressure chemical ionization tandem mass spectrometry applied for the ultra-fast quantitative analysis of BKM120 in human plasma.
Analytical and bioanalytical chemistry.
2014 Sep; 406(22):5413-23. doi:
10.1007/s00216-014-7966-6. [PMID: 24958346] - Alba Matas-Céspedes, Vanina Rodriguez, Susana G Kalko, Anna Vidal-Crespo, Laia Rosich, Teresa Casserras, Patricia Balsas, Neus Villamor, Eva Giné, Elías Campo, Gaël Roué, Armando López-Guillermo, Dolors Colomer, Patricia Pérez-Galán. Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).
Clinical cancer research : an official journal of the American Association for Cancer Research.
2014 Jul; 20(13):3458-71. doi:
10.1158/1078-0432.ccr-14-0154. [PMID: 24799524] - Maria Serova, Armand de Gramont, Annemilaï Tijeras-Raballand, Célia Dos Santos, Maria Eugenia Riveiro, Khemaies Slimane, Sandrine Faivre, Eric Raymond. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Cancer chemotherapy and pharmacology.
2013 May; 71(5):1297-307. doi:
10.1007/s00280-013-2129-6. [PMID: 23479136] - Hui Ren, Mingwei Chen, Ping Yue, Hui Tao, Taofeek K Owonikoko, Suresh S Ramalingam, Fadlo R Khuri, Shi-Yong Sun. The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
Cancer letters.
2012 Dec; 325(2):139-46. doi:
10.1016/j.canlet.2012.06.018. [PMID: 22781393] - Annett Mueller, Erika Bachmann, Monika Linnig, Katrin Khillimberger, Carl Christoph Schimanski, Peter R Galle, Markus Moehler. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Cancer chemotherapy and pharmacology.
2012 Jun; 69(6):1601-15. doi:
10.1007/s00280-012-1869-z. [PMID: 22543857] - Johanna C Bendell, Jordi Rodon, Howard A Burris, Maja de Jonge, Jaap Verweij, Diana Birle, David Demanse, Stefan S De Buck, Qinhua C Ru, Malte Peters, Michael Goldbrunner, José Baselga. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2012 Jan; 30(3):282-90. doi:
10.1200/jco.2011.36.1360. [PMID: 22162589]